Capvizr
THE DEAL, AT A GLANCE

Allogenetics

From the announcement
01
Therapeutic genesDelivery research
Gene therapy development
What it doesLed by CEO Oliver Ernst, PhD, Allogenetics is a biotechnology company developing an ex vivo gene therapy designed as a one-time treatment to modify donor organs, with…From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
02Who is involvedBacked by NBank Capital, CARMA FUND, Life Science Valley Wachstumsfonds, additional corporateFrom the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
03What happenedAllogenetics raised Pre-Series A, announced 2026-09-09From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
04Why it mattersAllogenetics raised €3.8 Million in a Pre-Series A round led by NBank Capital to advance an ex vivo gene therapy approach for organ transplantation outcomes.From the announcement

Summarized from the deal record's source announcement; not yet independently reviewed.

Read the announcement ↗
Click a part to explore its evidence. Unsupported imagery is withheld rather than guessed.Original record source ↗

Allogenetics · Financing Record

Explore source-linked visual explanations for Allogenetics. Unsupported claims are withheld while source review continues.

Record 12038 · Recorded date: 2026-09-09

Explore company records →
Free weekday briefing

Know which funding rounds matter before the first call.

Source-linked rounds, lead investors, and the signal behind the capital. One five-minute read.

Free · Unsubscribe anytime